BJH - volume 15, issue 2, march 2024
A.G.H. Niezink MD, R.W.M. van der Maazen MD, PhD, B.D.P. Ta MSc, H. Vos-Westerman MD, C.P.M. Janus MD, L.A. Daniels MD, PhD
Chimeric antigen receptor T-cell (CAR T-cell) therapy is available in the Netherlands as a third-line treatment option in patients with large B-cell lymphoma. Bridging is often required during the waiting period between leukapheresis and CAR T-cell infusion. Radiotherapy is an increasingly applied bridging strategy, which is well tolerated by patients and also safe and effective. The most commonly used radiation schedule is 20 Gy in five fractions. In addition to bridging, radiotherapy can also be used as consolidation or salvage treatment after CAR T-cell therapy. Involving a radiation oncologist in a timely manner for patients who are going to be treated with CAR T-cell therapy is of benefit.
(BELG J HEMATOL 2024;15(2):37–42)
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
